BCG |
= |
Bacillus Calmette - Guerin vaccines |
BP |
= |
Blood Pressure |
CCF |
= |
Congestive Cardiac Failure |
CNS |
= |
Central Nervous System |
CVP |
= |
Central Venous Pressure |
DC |
= |
Direct Current |
dpm |
= |
drops per minute |
DTLC |
= |
District TB and Leprosy Coordinator |
FBC |
= |
Full Blood Count |
g |
= |
gramme |
HIV |
= |
Human Immunodeficiency Virus |
HTLV |
= |
Human T - Cell Leukemia/Lymphonia Virus |
i.m(I.M) |
= |
intramuscular |
i.v(I.V) |
= |
intravenous |
l(L) |
= |
litre |
mm Hg |
= |
millimeters of mercury |
MU |
= |
mega unit |
ns |
= |
nanosecond |
O |
= |
oral |
PEM |
= |
protein energy malnutrition |
PHC |
= |
Primary Health Care |
PID |
= |
pelvic inflammatory disease |
PR |
= |
prosthion |
PIH |
= |
Pregnancy Induced Hypertension |
SC |
= |
Subcutaneous |
SLE |
= |
Systemic Lupus erythematous |
Tab |
= |
tablet |
TT |
= |
Tetanus Toxoid |
μg |
= |
microgram |
ARI |
= |
Acute Respiratory Infection |
STD |
= |
Sexually Transmitted Diseases |
SSS |
= |
Salt Sugar Solution |
APH |
= |
Antepartum Haemorrhage |
UTI |
= |
Urinary Tract Infection |
NS |
= |
Normal Saline- |
D&C |
= |
Dilation & Currettage |
ATS |
= |
Anti Tetanus Serum |
AE |
= |
Acute Epiglottis |
RR |
= |
Reversal Reaction |
MODIFICATION FORM
Please return the completed form to:-
The Chief Pharmacist
Ministry of Health
P.O. Box 9083
Dar es Salaam
Submission received from:
Name: .................................................................................................
Address: .............................................................................................
Telephone: ..........................................................................................
Signature: ............................................................................................
Date: ...................................................................................................
PLEASE INDICATE THE NATURE OF MODIFICATION BY MARKING THE APPROPRIATE BOX
Addition of a new disease to the list. (Please include epidemiological data as well as a treatment guideline)
Replacement of a listed drug. (Please include data on the proven benefits of the recommended drug in relation to the listed drug to be replaced).
Inclusion of a new drug. (Please include data on the benefits of such an addition)
PROPOSED MODIFICATION:
..........................................................................................
..........................................................................................
..........................................................................................
STG & NEDLIT 1997
PRINTED BY TANZANIA PRINTERS LIMITED, DAR ES SALAAM.
